Steven Roey, MD
Internal Medicine · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 32 years
- University of California, San Diego School of Medicine, 1994
Offices
1 location
Looking this up.
Hospitals listed: El Camino Health. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Roey’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A54912 · Current
Licensed to practise in California · since 1995 · expires 2027-03-31 · University of California, San Diego School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- El Camino HealthMountain View, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of El Camino Health, which runs 2 hospitalsPatients rate it 4 of 5 · 80% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.291, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.393, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0, Oct 2024 – Sep 2025
See every measure and the patient survey for El Camino Health
Behind the star rating — Deaths: 3 better, 5 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.291 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.393 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.96 (0.12 to 1.79) · 2,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.76 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.38 (125.03 to 209.73) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 68 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 185 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.9 · 814 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13 · 842 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 361 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.6 · 4,633 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.34) · 11,474 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.1 to 0.45) · 11,626 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.14 (1.39 to 4.9) · 2,814 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2 (0.61 to 3.39) · 1,327 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.8 to 3.43) · 2,641 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.39 (4.18 to 14.6) · 1,287 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 6.57 (3.47 to 9.68) · 1,308 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.14 (0.71 to 3.57) · 827 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.6 (0.05 to 1.15) · 9,460 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.5 · 122 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.993 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.706 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.376 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.5 · 218 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.5 · 962 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 3.8 · 200 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -17 · 922 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 18.6 · 860 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.7 · 827 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.1 (4.5 to 8.2) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (10.6 to 16.5) · 313 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.7 · 237 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.8 (10 to 16.1) · 1,639 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.8 to 1.1) · 1,619 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,535 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 86% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 87% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 80% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$53,334
Medicare paid this office $53,334 for 338 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 153 | $18,820 | $100 |
| Long return visit (40+ min) | 48 | $8,069 | $161 |
| Short return visit (20+ min) | 113 | $7,864 | $69 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 48 | $7,526 | $157 |
| Transitional care management services for problem of at least moderate complexity | 11 | $2,235 | $203 |
See all 8 services
| Return visit (30+ min) | 153 | $18,820 | $100 |
| Long return visit (40+ min) | 48 | $8,069 | $161 |
| Short return visit (20+ min) | 113 | $7,864 | $69 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 48 | $7,526 | $157 |
| Transitional care management services for problem of at least moderate complexity | 11 | $2,235 | $203 |
| Short return visit | 23 | $1,001 | $42 |
| Administration of pneumococcal vaccine | 12 | $435 | $36 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 23 | $407 | $14 |
Procedures Medicare counted
| Removal of skin lesions | 1-10 | None |
Who their Medicare patients are
338 Original Medicare patients in 2024. Average age 78 · Women 55% · Also on Medicaid 13% · Health risk score 1.08. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 70% · Coronary heart disease 28% · Chronic kidney disease 21% · Diabetes 20% · Atrial fibrillation 19% · Depression 19% · Heart failure 15% · Cancer 15% · Dementia 10% · COPD 9% · Stroke 7%.
The office billed $163,486, Medicare allowed $72,937 and paid $53,334; for 521 services of 22 kinds; $3,658 of it was for drugs given in the office and $49,676 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 338 | 521 | 78 | 1.08 | $163,486 | $53,334 |
| 2023 | 295 | 404 | 77 | 1.01 | $126,906 | $44,266 |
| 2022 | 278 | 405 | 78 | 1.02 | $107,773 | $42,265 |
| 2021 | 181 | 256 | 76 | 0.99 | $68,388 | $25,635 |
| 2020 | 87 | 128 | 78 | 1.13 | $33,792 | $11,354 |
| 2019 | 183 | 265 | 78 | 1.16 | $73,826 | $21,356 |
| 2018 | 204 | 294 | 77 | 1.12 | $77,085 | $22,861 |
| 2017 | 156 | 215 | 77 | 0.98 | $54,393 | $15,823 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Return visit (30+ min) | 96 | $12,563 | $103 |
| Short return visit (20+ min) | 108 | $7,923 | $69 |
| Long return visit (40+ min) | 48 | $7,846 | $151 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 44 | $7,020 | $160 |
| Transitional care management services for problem of at least moderate complexity | 14 | $2,853 | $204 |
| Short return visit | 16 | $739 | $46 |
2022: 7 services
| Return visit (30+ min) | 112 | $14,408 | $113 |
| Short return visit (20+ min) | 93 | $8,114 | $84 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 43 | $6,789 | $158 |
| Long return visit (40+ min) | 26 | $3,756 | $144 |
| Short return visit | 28 | $1,326 | $47 |
| Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | 12 | $843 | $70 |
| Administration of influenza virus vaccine | 11 | $415 | $38 |
2021: 4 services
| Return visit (30+ min) | 85 | $11,556 | $110 |
| Short return visit (20+ min) | 63 | $5,053 | $78 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 23 | $3,349 | $146 |
| Long return visit (40+ min) | 17 | $2,984 | $166 |
2020: 2 services
| Return visit (30+ min) | 60 | $7,190 | $98 |
| Short return visit (20+ min) | 16 | $686 | $40 |
2019: 3 services
| Return visit (30+ min) | 96 | $11,433 | $89 |
| Short return visit (20+ min) | 80 | $5,467 | $61 |
| Long return visit (40+ min) | 16 | $2,088 | $123 |
2018: 3 services
| Return visit (30+ min) | 123 | $14,124 | $90 |
| Short return visit (20+ min) | 79 | $4,517 | $56 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 11 | $1,445 | $131 |
2017: 3 services
| Return visit (30+ min) | 67 | $7,111 | $90 |
| Short return visit (20+ min) | 82 | $5,150 | $57 |
| Long return visit (40+ min) | 12 | $1,599 | $114 |
Drugs they prescribed that Part D paid
$51,313
Pharmacies billed $51,313 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 4% of their Part D prescriptions (32 of 754) in 2024. Above the middle of the specialty; the typical internal medicine clinician is at 1%.
669 generic and fewer than 11 brand-name prescriptions · $51,313 in drug cost · 31 antibiotic prescriptions to 28 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Sertraline | 15 | $998 | $67 |
| Venlafaxine Hcl Er | 15 | $528 | $35 |
| Omeprazole | 21 | $425 | $20 |
| Atorvastatin | 51 | $410 | $8 |
| Gabapentin | 21 | $311 | $15 |
See all 18 drugs
| Sertraline | 15 | $998 | $67 |
| Venlafaxine Hcl Er | 15 | $528 | $35 |
| Omeprazole | 21 | $425 | $20 |
| Atorvastatin | 51 | $410 | $8 |
| Gabapentin | 21 | $311 | $15 |
| Hydrocodone-Acetaminophen | 16 | $215 | $13 |
| Lisinopril | 37 | $184 | $5 |
| Cyclobenzaprine | 12 | $132 | $11 |
| Tamsulosin | 12 | $120 | $10 |
| Amlodipine Besylate | 29 | $114 | $4 |
| Ketoconazole | 12 | $113 | $9 |
| Levothyroxine | 19 | $108 | $6 |
| Zolpidem | 16 | $69 | $4 |
| Losartan | 19 | $51 | $3 |
| Sildenafil Citrate | 11 | $33 | $3 |
| Hydrochlorothiazide | 11 | $32 | $3 |
| Azithromycin | 11 | $29 | $3 |
| Paxlovid | 14 | $0 | $0 |
Year by year
| 2024 | 754 | 239 | 4% (32) | None | $51,313 |
| 2023 | 679 | 195 | 5% (35) | 8% | $34,600 |
| 2022 | 656 | 185 | 6% (38) | 9% | $27,521 |
| 2021 | 312 | 94 | None | 8% | $19,154 |
| 2020 | 319 | 87 | None | None | $11,508 |
| 2019 | 454 | 179 | 9% (40) | None | $28,504 |
| 2018 | 455 | 170 | 14% (64) | 15% | $23,550 |
| 2017 | 235 | 120 | 15% (35) | None | $12,770 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Synthroid | 11 | $840 | $76 |
| Atorvastatin | 43 | $552 | $13 |
| Tamsulosin | 23 | $426 | $19 |
| Furosemide | 26 | $405 | $16 |
| Omeprazole | 19 | $385 | $20 |
| Ipratropium | 16 | $374 | $23 |
| Potassium Chloride | 12 | $369 | $31 |
| Hydrocodone-Acetaminophen | 16 | $333 | $21 |
| Gabapentin | 22 | $325 | $15 |
| Amlodipine Besylate | 16 | $251 | $16 |
| Losartan | 20 | $225 | $11 |
| Carvedilol | 12 | $204 | $17 |
| Lisinopril | 24 | $193 | $8 |
| Paxlovid (Eua) | 11 | $111 | $10 |
| Hydrochlorothiazide | 14 | $79 | $6 |
2022: 16 drugs
| Losartan | 18 | $497 | $28 |
| Metoprolol | 12 | $458 | $38 |
| Gabapentin | 25 | $395 | $16 |
| Paroxetine | 15 | $395 | $26 |
| Hydroxyurea | 12 | $387 | $32 |
| Tamsulosin | 20 | $342 | $17 |
| Fluticasone Propionate | 16 | $323 | $20 |
| Lisinopril | 25 | $288 | $12 |
| Furosemide | 24 | $276 | $11 |
| Hydrocodone-Acetaminophen | 16 | $272 | $17 |
| Amlodipine Besylate | 18 | $223 | $12 |
| Atorvastatin | 25 | $204 | $8 |
| Sildenafil Citrate | 11 | $128 | $12 |
| Buspirone | 11 | $115 | $10 |
| Triamcinolone Acetonide | 12 | $82 | $7 |
| Hydrochlorothiazide | 19 | $55 | $3 |
2021: 7 drugs
| Losartan | 15 | $366 | $24 |
| Pravastatin | 11 | $340 | $31 |
| Atorvastatin | 27 | $332 | $12 |
| Gabapentin | 11 | $280 | $25 |
| Amlodipine Besylate | 16 | $264 | $17 |
| Lisinopril | 29 | $195 | $7 |
| Tamsulosin | 11 | $161 | $15 |
2020: 9 drugs
| Pravastatin | 11 | $537 | $49 |
| Atorvastatin | 28 | $404 | $14 |
| Fluticasone Propionate | 14 | $343 | $24 |
| Lisinopril | 29 | $246 | $8 |
| Metformin | 11 | $210 | $19 |
| Tamsulosin | 12 | $172 | $14 |
| Amlodipine Besylate | 20 | $133 | $7 |
| Losartan | 14 | $125 | $9 |
| Diazepam | 12 | $24 | $2 |
2019: 8 drugs
| Hydrocodone-Acetaminophen | 24 | $480 | $20 |
| Atorvastatin | 23 | $401 | $17 |
| Fluticasone Propionate | 14 | $213 | $15 |
| Lisinopril | 24 | $160 | $7 |
| Furosemide | 19 | $115 | $6 |
| Zolpidem | 12 | $69 | $6 |
| Amlodipine Besylate | 12 | $69 | $6 |
| Diazepam | 13 | $26 | $2 |
2018: 7 drugs
| Hydrocodone-Acetaminophen | 29 | $611 | $21 |
| Atorvastatin | 16 | $355 | $22 |
| Lisinopril | 15 | $154 | $10 |
| Allopurinol | 11 | $130 | $12 |
| Zolpidem | 15 | $111 | $7 |
| Hydrochlorothiazide | 16 | $77 | $5 |
| Furosemide | 13 | $67 | $5 |
2017: 1 drug
| Hydrocodone-Acetaminophen | 12 | $223 | $19 |
Professional record
- NPI
- 1982709093
- Licence
- CA A54912California A54912: Current · expires 2027-03-31
- Trained
- University of California, San Diego School of Medicine, 1994 · 32 years ago
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00A549120
- Taxonomy
- Internal medicine (207R00000X)
- Mailing address
- 2350 W. El Camino Real, 2nd Floor, Mountain View, CA, 94040
- NPI first listed
- 2006-09-13
- NPI last updated
- 2017-02-03
This is when the NPI record was last certified, not a medical board exam.